Physician profile
Thomas Tasaki
NPI 1235169806
$1,140.43
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $317 · 2021: $111 · 2022: $85.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $211.63 | 2019-2022 | |
| Amgen INC. | $160.61 | 2019-2021 | |
| Travere Therapeutics, INC. | $144.86 | 2019-2020 | |
| Amicus Therapeutics, INC. | $123.74 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $116.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $104.23 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $71.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $47.42 | 2019-2021 | |
| Horizon Therapeutics Plc | $45.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.43 | 2019 | |
| Glaxosmithkline, LLC. | $35.04 | 2019-2020 | |
| Akebia Therapeutics INC | $34.96 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tasaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.